Pfizer/Eyetech Sets Sights On Diabetic Macular Edema For Macugen Sales Growth

Eyetech and Pfizer will initiate a Phase II/III pivotal trial during the second half of the year, Eyetech said. The age-related macular degeneration market, for which Macugen is currently approved, may face increasing competition